Evidence map›Paper›PMID 33578882›Full record

ArticlePharmaceutics2021

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer.

Ramya Lakshmi Rajendran, Sanjita Paudel, Prakash Gangadaran, Ji Min Oh, Eun Jung Oh, Chae Moon Hong, Sangkyu Lee, Ho Yun Chung, Jaetae Lee, Byeong-Cheol Ahn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. The emerging role of extracellular vesicles in retinal diseases.American journal of translational research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ramya Lakshmi RajendranDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Sanjita PaudelBK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea.
Prakash GangadaranDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Ji Min OhDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Eun Jung OhDepartment of Plastic and Reconstructive Surgery, CMRI, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Korea.ORCID 0000-0002-5139-9870
Chae Moon HongDepartment of Nuclear Medicine, Kyungpook National University Hospital, Daegu 41404, Korea.
Sangkyu LeeBK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea.
Ho Yun ChungBK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Jaetae LeeDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Byeong-Cheol AhnDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea.ORCID 0000-0001-7700-3929
Kyungpook National University · KRKyungpook National University Hospital · KR

Funding

National Research Foundation of Korea NRF-20191A6A3A13096414National Research Foundation of Korea NRF-2019R1I1A1A01061296National Research Foundation of Korea NRF-2019R1I1A3A01059909National Research Foundation of Korea NRF-2019R1I1A3A01063308
6 · The paper itself

Abstract

A new approach for using extracellular vesicles (EVs) to deliver tyrosine kinase inhibitors (TKIs) to enhance iodine avidity in radioactive iodine-refractory thyroid cancer is needed. We isolated and characterized primary human adipose-derived stem cells (ADSCs) and isolated their EVs. The EVs were characterized by transmission electron microscopy, nanoparticle tracking analysis, and western blotting. A new TKI was loaded into the EVs by incubation (37 °C; 10 min) or sonication (18 cycles; 4 s per cycle) with 2 s intervals and a 2 min ice bath every six cycles. TKI loading was confirmed and measured by mass spectrometry. EV uptake into radioactive iodine-refractory thyroid cancer cells (SW1736 cells) was confirmed by microscopy. We treated the SW1736 cells with vehicle, TKI, or TKI-loaded EVs (sonication TKI-loaded EVs [EVs

Indexed as

drug deliveryextracellular vesiclesradioactive iodinethyroid cancertyrosine kinase inhibitor

Identifiers

PMID33578882
PMCPMC7916551
OpenAlexW3126852293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.